Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
È importante, per noi di Euro Company, essere un punto di riferimento per un’alimentazione sana e sostenibile, mettendo al centro la salute, il pianeta e il rispetto delle persone, con l’obiettivo ultimo di influenzare l’intera industria
Euro Company cerca un/a Brand Manager per gestire l’identità del brand e sviluppare strategie di marketing. La figura scelta garantirà la coerenza della comunicazione e collaborerà allo sviluppo di nuovi prodotti. È richiesta una laurea in
Euro Company mette al centro delle proprie azioni quotidiane la Qualità e la Sicurezza Alimentare, per garantire prodotti eccellenti ai propri clienti. L’Area Qualità lavora ogni giorno per assicurare elevatissimi standard, affidandosi alla migliore tecnologia presente
業界トップティアに名を連ねるうえで、最重要の役割を担う人材採用ポジション。 企業が目指す”一流のITプロフェッショナル”へと一緒に歩む有望株をあなたの手で発掘してみませんか？ AIを核に企業のDXを推進するためのマルチプロダクト展開およびコンサルティングソリューションを提供する、約600名規模のベンチャー企業です。 近年では毎年130～140％の事業成長を実現し、IPOに向けさらなる組織拡大を進めています。 今、世に知られる多くのSaaSエンタープライズ企業は、500名から1,000名規模への飛躍的な組織拡大を“採用”によって実現してきました。 採用に成功した企業から順に、業界を代表する企業へと成長を遂げています。 仕事内容 ■ オペレーター業務 ・面接日程調整 ・書類管理／ATS管理 ・エージェント・媒体対応 ・採用関連庶務 ■ リクルーター業務 ・候補者フォロー／クロージング ・チャネルごとの効果分析／仮説検証 ・スクリーニング／面接対応 事業内容 HRテック事業 マーケティングDX事業 オペレーションDX事業 AI開発支援事業 サイバーセキュリティ事業 Requirements 必須要件 ・採用担当として日程調整、ATS管理、エージェント／スカウト媒体対応の経験をお持ちの方 ・HR領域での営業経験をお持ちの方（CA／RA、求人広告／媒体など） 歓迎要件 ・成長フェーズのベンチャー企業で組織生成に貢献できる方 ・事業会社の中途採用担当としての経験3年以上 ・人材領域にて3年以上の経験（人材紹介営業、媒体営業など） 求める人物像 ・生成AIやITへの興味があり、業務で活用している方 ・ITリテラシーをお持ちの方 ・チームや組織に貢献できる方 Benefits
Euro Company pone da sempre al centro della propria visione le persone, riconoscendo il valore unico di ogni collaboratore e il contributo fondamentale che ciascuno offre al successo dell’intera filiera produttiva. Crediamo che la crescita dell’azienda
Euro Company mette al centro del proprio interesse i suoi collaboratori, consapevole che ogni figura presente in azienda sia fondamentale per il buon funzionamento dell’intera filiera produttiva. Se sei interessat* ad un ruolo operativo in ambito
Ras Interim busca un/a operari/ària per la seva empresa de pales de pàdel situada a Tona. La feina inclou responsabilitats com matisar, preparar màquines CNC, controlar la qualitat i tallar material. Consulte la descripción del puesto a
Se necesita un soldador con experiencia en los procesos MIG MAG y electrodo revestido para trabajar en el sector ferroviario, concretamente en el montaje, reparación y mantenimiento de vagones y locomotoras. Las tareas incluyen la aplicación